Kornimate/medical-research-clean huggingface dataset:
combined transcranial magnetic stimulation and cognitive treatment in blast traumatic brain injury

Conditions: Traumatic Brain Injury; Cognitive Dysfunction; Blast Injury

Summary: this study investigates the efficacy of a novel neurorehabilitation program combining noninvasive brain stimulation (transcranial magnetic stimulation or tms) and cognitive therapy, on cognitive function and quality of life in individuals with blast-induced traumatic brain injury (btbi).

the most common blast-induced traumatic brain injury (btbi)-associated problems are cognitive deficits, such as executive functioning and memory. this study evaluates a combined rehabilitation program: transcranial magnetic stimulation (tms) and cognitive therapy for treatment of patients with btbi. tms is a noninvasive way of stimulating the brain, which is not painful and does not involve any needles or any form of surgery. it acts by delivering a magnetic stimulation to a particular brain region. half of the study participants will receive cognitive intervention with active tms, and a control group will receive cognitive intervention with sham tms. this study takes place in boston, massachusetts: at the va boston healthcare system and beth israel deaconess medical center.

Eligibility criteria:
inclusion criteria: * oef/oif active-duty personnel or veterans exposed to blast * meets criteria for mild tbi * loc of 30 min or less * age: 21-50 * primary language is english exclusion criteria: * evidence of penetrating head injury * history of previous neurological diagnosis * history of previous psychotic disorder prior to the blast exposure * hearing or vision impairment

Keywords: blast traumatic brain injury cognitive rehabilitation transcranial magnetic stimulation combined treatment
dopaminergic enhancement of learning and memory in aphasia

Conditions: Cerebrovascular Accident; Aphasia

Summary: the purpose of this study is to determine whether levodopa, in combination with a high frequency language training, is effective in boosting naming performance in patients with aphasia.

our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. in this randomized, placebo-controlled, double-blind clinical trial, we probe whether daily administration of levodopa, coupled with several hours of language training every day, will significantly improve naming abilities in patients with aphasia as compared to placebo administration. we furthermore examine with magnetic resonance imaging which brain regions need to be functionally intact for a dopaminergic improvement of language therapy.

Eligibility criteria:
inclusion criteria for patients with aphasia: * unilateral cerebrovascular accident (stroke) in the territory of the arteria media * time post onset: \> 6 months * aphasia with anomia * age between 18-75 years * premorbid right-handedness * primary language: german exclusion criteria for patients and healthy controls: * known allergy to levodopa or tartrazine * history of medication/drug abuse * acute nicotine withdrawal or \> 15 cigarettes per day * \> 6 cups/glasses of coffee, caffeine drinks or energy drinks per day * \> 50 grams of alcohol per day * severe hypertonia (systole \>180 mm hg) * severe arteriosclerosis * diabetes, asthma, or glaucoma * severe hearing disability * evidence for severe hippocampal damage * premorbid depression or psychosis * medication with dopamine agonists or antagonists * parkinsonian symptoms * changes in anticonvulsive medication during the week prior to study enrollment

Keywords: language acquisition plasticity stroke recovery aphasia treatment naming levodopa stroke
bosutinib for autosomal dominant polycystic kidney disease

Conditions: Polycystic Kidney, Autosomal Dominant

Summary: this purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (adpkd) entering the study with a total kidney volume greater than or equal to 750 cc and egfr greater than or equal to 60 ml/min/1.73m2.


Eligibility criteria:
inclusion criteria: * males and females, 18 to 50 years old at the time of consent. * documented diagnosis of adpkd (pkd-1 or pkd-2 genotypes allowed). * total kidney volume ≥ 750 cc, as measured by centrally evaluated mri. exclusion criteria: * egfr \< 60 ml/min/1.73m2. * uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm hg). * any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (pkd) therapies.

Keywords: bosutinib autosomal dominant polycystic kidney disease
improving end of life care in head and neck cancer

Conditions: The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the; Upper Aerodigestive Tract

Summary: the purpose of this study is to improve the quality of care provided for head and neck cancer patients. by better understanding the end of life experiences of dying patients and their families, the investigators hope to better anticipate and improve upon the experiences of future patients and their families.


Eligibility criteria:
inclusion criteria: * head and neck cancer patients who received their treatment at mskcc who have died of noncutaneous squamous cell carcinomas of the upper aerodigestive tract and for whom family / next of kin contact information is available. * time of patient death must have been at least 6 months ago and no more than 4 years ago * patient age at time of death must be over 21 years of age. * those interviewed must be english-fluent. exclusion criteria: * non-english speaking interviewees * next-of-kin who reported being unfamiliar with care received during the last month of life * next-of-kin who did not identify themselves as one of the patient's primary social supports during the last month of life * next-of-kin who were not physically present with the deceased at least once during the last week of his/her life * next-of-kin under age 21

Keywords: 12-136
endoscopic mucosal injection versus ultrasound-guided injection of triamcinolone to treat subglottic stenosis

Conditions: Subglottic Stenosis

Summary: this study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. these groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. the comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. the safety and effectiveness will be compared to determine the relative merits of the two treatment methods.


Eligibility criteria:
inclusion criteria: * 1: "diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as ct." * 2: "experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc." exclusion criteria: * 1: "severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure." * 2: "patients allergic to lidocaine, midazolam, triamcinolone, or any of their components." * 3: "pregnant or lactating women." * 4: "unstable angina, congestive heart failure, severe bronchial asthma." * 5: "severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (pao2 \<60mmhg after oxygen therapy or mechanical ventilation)." * 6: "known coagulation dysfunction, inability to stop anticoagulants, antiplatelet agents, aspirin, or nonsteroidal anti-inflammatory drugs before treatment." * 7: "patients do not agree to participate in this study." * 8: "participation in other studies within the last three months and not withdrawn or concluded, or having received triamcinolone treatment less than 1 month ago." * 9: "researchers believe there are any circumstances making the patient unsuitable for inclusion."

Keywords: subglottic stenosis triamcinolone translaryngeal endoscopic mucosal injection ultrasound-guided injection
a study of efficacy and safety of rosnilimab in subjects with moderate to severe rheumatoid arthritis (renoir)

Conditions: Rheumatoid Arthritis

Summary: renoir study: this study will evaluate the safety, tolerability, and efficacy of rosnilimab in subjects with moderate to severe rheumatoid arthritis (ra)

this study is a phase 2 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rosnilimab in subjects with moderate to severe rheumatoid arthritis.

Eligibility criteria:
key inclusion criteria: * aged 18 years or older * a diagnosis of rheumatoid arthritis based on acr/eular 2010 classification criteria, for at least 3 months before participating in the trial * must be receiving treatment with at least 1, but not more than 2 csdmards for at least 3 months and be on stable dosages for at least 8 weeks prior to joining and throughout the trial * have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic dmard (csdmard), biologic dmard (bdmard), or targeted synthetic dmard (tsdmard) treatment key exclusion criteria: * history of an inflammatory joint disease other than rheumatoid arthritis * prior exposure to a pd-1 or pd-l1 agonist, antagonist, or modulator * history of cancer within the last 5 years (except for some skin cancers) * any known or suspected condition that would compromise immune status * pregnant or breastfeeding women

Keywords: pd-1 agonist anb030 renoir rosnilimab
acupuncture point stimulation for treatment of chemotherapy nausea and vomiting

Conditions: Childhood Acute Lymphoblastic Leukemia; Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies; Ewing Sarcoma; Vomiting in Infants and/or Children; Osteosarcoma

Summary: this randomized pilot clinical trial studies giving acupuncture in reducing nausea and vomiting in patients undergoing chemotherapy. pressing and stimulating nerves at an acupuncture point on the inside of the wrist may help control nausea and vomiting during chemotherapy.

primary objective: i. to determine whether transcutaneous acupuncture point stimulation (taps) at p6 as an adjuvant treatment to standard antiemetic therapy reduces acute chemotherapy induced nausea and vomiting as compared to sham acupuncture point stimulation in children undergoing their first round of highly or moderately emetogenic chemotherapy. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients undergo taps at the true acupuncture point (p6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. patients then crossover to arm ii for the second course of chemotherapy. arm ii: patients undergo taps at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. patients then crossover to arm i for the second course of chemotherapy.

Eligibility criteria:
inclusion criteria: * patient with a planned admission for at least 24 hours for highly emetogenic or moderately emetogenic chemotherapy at lucile packard children's hospital or packard el camino. * planned to undergo at least 2 more cycles of chemotherapy. * can include but not limited to: children with high risk all, aml, ewing's sarcoma, osteosarcoma * history of vomiting with prior cycles of chemotherapy (2 episodes of emesis at minimum) despite use of conventional antiemetic medications. * age 8-21. * parent must be able to understand and willing to sign written informed consent document. exclusion criteria: * prior knowledge of acupuncture or experience with acupuncture or acupressure. * there will be no restrictions regarding use of other investigational agents. * comorbid diseases: * diagnosis of any cardiac condition (cardiomyopathy, arrhythmia, pacemaker placement). * any diagnosis requiring pediatric intensive care unit admission. * patients with brain tumor, brain metastasis (these patients often require radiation and surgery in addition to chemotherapy which may confound the results) * concomitant radiation therapy during current chemotherapy cycle. * developmental delay patients with allergy to tape or leads will be excluded from the study. * pregnant patients will be excluded from the study. * cancer survivors will not be excluded from the study as long as they are undergoing chemotherapy treatment for their current cancer therapy. * hiv-positive patients will not be excluded.
comparison tympanoplasty with membrane amniotic and autologous fascia

Conditions: Tympanic Membrane Perforation

Summary: the tympanic membrane separates the middle and the outer ear from each other and consists of three layers. the outer layer is covered with squamous epithelium, a thick basement membrane in the middle and an inner mucosal layer. rupture of the tympanic membrane is common cause of hearing loss. in spite of the ability to spontaneously healing of the tympanic membrane, chronic tear of the eardrum in the absence of its spontaneously healing indicates surgical management. these surgeries are performing using various materials including fascia, cartilage, fats, pericardium and paper patch. it has proven that using different materials results in outcome and postoperative complications. the criteria of the best graft material includes availability, preservability, manageability, and acceptance rate to the hosts. human amniotic membrane is preservable. also, there isn't significant immunologic reactions against such graft material. so, choosing the best graft for tympanoplasty surgery decreases complications, hospitalizations after surgery, and costs, consequently. up to now, limited studies have been conducted on the patients who were used amniotic membrane in the surgical reconstruction. there are different outcomes and complications which depend on the size of the rupture and the problems associated with the surgical conditions. considering that it can reduce the surgical time and cost of surgery, and with its high success rate, it can even be used as a substitute for conventional methods. the aim of this study was to compare the result of surgical repair of the tympanic membrane using membrane amniotic and surgical tympanoplasty with autologous fascia. here the investigators reported on 30 patients who underwent typmanoplasty with amniotic membrane and temporalis fascia grafting.


Eligibility criteria:
inclusion criteria: - exclusion criteria: * acute otorrhea / - cholesteatomas / - canal stenosis requiring canaloplasty / - immunosuppressive patients / - active neoplasm / - diabetes mellitus / - ruptures less than one fifth of the eardrum / - smoking.

Keywords: amniotic membrane tympanic membrane perforation
a comparative study of mammography and ultrasound for breast cancer screening and early diagnosis

Conditions: Breast Cancer Diagnosis; Breast Cancer Screening

Summary: improving the early diagnosis of breast cancer can reduce mortality. with mammography as the main tool for screening early breast cancer, the characteristics of dense breast and young onset of disease in chinese women lowers the efficiency. the aim of this prospective study was to compare which method, x-ray or ultrasound, is more appropriate for screening and early diagnosis of breast cancer in chinese women.

breast cancer has become the most common malignancy in women. improving the early diagnosis of breast cancer can reduce mortality. mammography is recommended as the main tool for screening and early diagnosis of breast cancer in the guidelines of european and american countries. however, the characteristics of dense breast and young onset of disease in chinese women make the screening and early diagnosis strategies of western countries, which are mainly based on mammography, unsuitable for chinese women. the aim of this prospective study was to compare which method, x-ray or ultrasound, is more appropriate for screening and early diagnosis of breast cancer in chinese women.

Eligibility criteria:
inclusion criteria: * informed consent, subjects 35-70 years old, asymptomatic, able to undergo ultrasound and x-ray exclusion criteria: * localized breast erythema and ulceration, pregnancy, lactation, after previous breast implantation, already pathologically definite breast cancer patients

Keywords: mammography ultrasound breast cancer screening early diagnosis
evaluation of physician training methods to read florbetapir-pet scans

Conditions: Alzheimer's Disease

Summary: the purpose of this study is re-read of brain amyloid positron emission tomography (pet) scans acquired in previous florbetapir f 18 clinical studies by readers trained using updated reading methodology. the scans in this study came from subjects who had an autopsy to reveal the subject's true amyloid status.


Eligibility criteria:
inclusion criteria (study a07\[nct00857415\]): * have a projected life expectancy of ≤ 6 months as determined by the principal investigator (e.g. terminal medical condition) or are already enrolled in a longitudinal study of aging with an autopsy component; * can tolerate a 10 minute pet scan; and * give informed consent for study procedures and brain donation consistent with the legal requirements of the state in which they are enrolled and the state in which they die. exclusion criteria (study a07\[nct00857415\]): * have primary brain tumor, known metastases to the brain, central nervous system (cns) lymphoma; * have any major, focal structural loss of brain matter; * are aggressively being treated with life sustaining measures (e.g. currently on respirator; receiving high dose chemotherapy); * have a clinically significant infectious disease, including acquired immune deficiency syndrome (aids), human immunodeficiency virus (hiv) infection, previous positive test for hepatitis or hiv or creutzfeldt-jakob disease (cjd); * are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days; * have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, secretase inhibitor); * have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session; or * are females of childbearing potential who are pregnant or not using adequate contraception.

Keywords: amyloid imaging positron emission tomography 18f-av-45 florbetapir f 18 diagnostic imaging
retinyl palmitate-loaded ethosomes in acne vulgaris

Conditions: Facial Acne Vulgaris

Summary: acne is a chronic inflammatory dermatosis of the pilosebaceous unit. topical treatment is the first choice in mild and moderate cases of acne, especially topical retinoids. although topical retinoids are very effective in the treatment of acne, local cutaneous irritation including burning, itching, erythema, peeling or dryness, is observed in a considerable number of patients, resulting in low patient compliance, compromising the efficacy of the therapy. several approaches have been proposed to address these concerns, including the use of esters of retinoic acid (ra) and ra precursors, such as retinol and retinaldehyde, or novel drug delivery systems, which present the potential for controlled release, in turn reducing the aforementioned occurrences. encapsulation of retinoids into vesicular carriers as liposomes and ethosomes and nanoparticulate carriers can significantly improve their effects for the treatment of acne compared with commercial formulations , providing better tolerability of irritating retinoid. the aim of work is to assess the efficacy and tolerability of the topical application of retinyl palmitate-loaded ethosome formulation in the treatment of acne vulgaris in comparison to conventional formulation of classic retinoids


Eligibility criteria:
inclusion criteria: * patients with facial mild to moderate acne vulgaris * patients aged 12-40 years old exclusion criteria: * pregnant females * patients with skin condition of the face such as rosacea, perioral dermatitis, atopic or seborrheic dermatitis or psoriasis. * patients with known hypersensitivity to preparations containing retinoid. * patients who take any other cocomitant systemic or topical medications for acne vulgaris

Keywords: acne vulgaris retinoids retinyl palmitate ethosomes
tpn-induced hyperglycemia: impact on clinical outcome in intensive care unit (icu) and non-icu patients

Conditions: Hyperglycemia

Summary: a growing body of evidence suggests hyperglycemia is associated with adverse outcomes in patients with and without diabetes. observational studies document an association between hyperglycemia and poor clinical outcomes in cardiothoracic surgery, elective surgery, myocardial infarction, stroke. randomized studies indicate glycemic control is associated with improved outcomes in diabetic patients with critically illness. hyperglycemia is a recognized and common complication of patients receiving total parenteral nutrition (tpn). few studies in the literature have looked into the impact of tpn-associated inhospital complications and mortality. accordingly, this study aims to evaluate the impact of hyperglycemia on clinical outcome (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay, and mortality) in patients receiving tpn. we will perform a retrospective chart review of all patients treated with tpn from 1/01/06 to 12/31/06 at grady memorial hospital. we hypothesize that patients receiving tpn who develop hyperglycemia experience higher morbidity (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay) and mortality compared to tpn patients with euglycemia. the results of this study will help us to formulate a prospective randomized clinical trial on the management of tpn-associated hyperglycemia in hospitalized patients. this study aims to evaluate the impact of hyperglycemia on clinical outcome (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay, in hospital mortality) in patients receiving total parenteral nutrition. we will perform a retrospective chart review of all patients admitted to the hospital receiving tpn from 1/01/06 to 12/31/06 at grady memorial hospital. the results of this study will help us to formulate a prospective randomized clinical trial on the management of tpn-associated hyperglycemia in hospitalized patients.

hypotheses: we hypothesize that patients receiving tpn who develop hyperglycemia experience higher morbidity (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay) and mortality compared to tpn patients with euglycemia. specific aim: to determine the impact of hyperglycemia on clinical outcome (infection, systemic sepsis, cardiac complications, acute renal failure, length of stay, mortality) in patients receiving total parenteral nutrition.

Eligibility criteria:
inclusion criteria: perform a retrospective chart analysis of all patients receiving tpn at grady memorial hospital during the period of 1/01/06 to 12/31/06. exclusion criteria: none except for charts without adequate data sufficient for chart review.

Keywords: diabetes nutrition/dietics clinical outcomes total parenteral nutrition